Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection

Journal of Clinical Oncology

Volumn 30, Issue 6, 2012, Pages 623-630

  Tsan, Yu Tse ^a,c,d   Lee, Chang Hsing ^a,e   Wang, Jung Der ^a,b,f   Chen, Pau Chung ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e Ton Yen General Hospital   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADEFOVIR DIPIVOXIL; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENTECAVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; LAMIVUDINE; TELBIVUDINE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER RISK; DATA BASE; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION;

ADULT; CARCINOMA, HEPATOCELLULAR; CHILD; COHORT STUDIES; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATITIS B; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK FACTORS; TAIWAN; YOUNG ADULT;

EID: 84863115964     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.0917     Document Type: Article

References (65)

1. Baigent C, Keech A, Kearney PM, et al: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-1278, 2005
2. Hebert PR, Gaziano JM, Chan KS, et al: Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trials. JAMA 278:313-321, 1997 (Pubitemid 27339660)
3. Kjekshus J, Apetrei E, Barrios V, et al: Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357:2248-2261, 2007 (Pubitemid 350190755)
4. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355:549-559, 2006 (Pubitemid 44202151)
5. Sassano A, Platanias LC: Statins in tumor suppression. Cancer Lett 260:11-19, 2008
6. Newman TB, Hulley SB: Carcinogenicity of lipid-lowering drugs. JAMA 275:55-60, 1996 (Pubitemid 26004257)
7. Wong WW, Dimitroulakos J, Minden MD, et al: HMG-CoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16:508-519, 2002 (Pubitemid 34460459)
8. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 343:425-430, 1990
9. Keyomarsi K, Sandoval L, Band V, et al: Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51: 3602-3609, 1991
10. Kusama T, Mukai M, Iwasaki T, et al: 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122:308-317, 2002 (Pubitemid 34116983)
11. Weis M, Heeschen C, Glassford AJ, et al: Statins have biphasic effects on angiogenesis. Circulation 105:739-745, 2002 (Pubitemid 34157379)
12. Gauthaman K, Fong CY, Bongso A: Statins, stem cells, and cancer. J Cell Biochem 106:975-983, 2009
13. Chan KK, Oza AM, Siu LL: The statins as anticancer agents. Clin Cancer Res 9:10-19, 2003 (Pubitemid 36109711)
14. Dimitroulakos J, Marhin WH, Tokunaga J, et al: Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia 4:337-346, 2002 (Pubitemid 34755844)
15. Jacobs EJ, Newton CC, Thun MJ, et al: Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 71:1763-1771, 2011
16. Friis S, Poulsen AH, Johnsen SP, et al: Cancer risk among statin users: A population-based cohort study. Int J Cancer 114:643-647, 2005 (Pubitemid 40349625)
17. Poynter JN, Gruber SB, Higgins PD, et al: Statins and the risk of colorectal cancer. N Engl J Med 352:2184-2192, 2005 (Pubitemid 40727085)
18. Karp I, Behlouli H, Lelorier J, et al: Statins and cancer risk. Am J Med 121:302-309, 2008 (Pubitemid 351417853)
19. Dale KM, Coleman CI, Henyan NN, et al: Statins and cancer risk: A meta-analysis. JAMA 295:74-80, 2006 (Pubitemid 43042692)
20. Browning DR, Martin RM: Statins and risk of cancer: A systematic review and metaanalysis. Int J Cancer 120:833-843, 2007 (Pubitemid 46175404)
21. Alsheikh-Ali AA, Maddukuri PV, Han H, et al: Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: Insights from large randomized statin trials. J Am Coll Cardiol 50:409-418, 2007 (Pubitemid 47096680)
22. Kim K: Statin and cancer risks: From tasseomancy of epidemiologic studies to meta-analyses. J Clin Oncol 24:4796-4797, 2006
23. de Denus S, Spinler SA, Miller K, et al: Statins and liver toxicity: A meta-analysis. Pharmacotherapy 24:584-591, 2004 (Pubitemid 38585952)
24. Lewis JH, Mortensen ME, Zweig S, et al: Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 46:1453-1463, 2007 (Pubitemid 350155527)
25. Hippisley-Cox J, Coupland C: Unintended effects of statins in men and women in England and Wales: Population based cohort study using the QResearch database. BMJ 340:c2197, 2010
26. Hippisley-Cox J, Coupland C: Individualising the risks of statins in men and women in England and Wales: Population-based cohort study. Heart 96:939-947, 2010
27. Chiu HF, Ho SC, Chen CC, et al: Statin use and the risk of liver cancer: A population-based case-control study. Am J Gastroenterol 106:894-898, 2011
28. Kawata S, Yamasaki E, Nagase T, et al: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma: A randomized controlled trial. Br J Cancer 84:886-891, 2001 (Pubitemid 32385829)
29. El-Serag HB, Johnson ML, Hachem C, et al: Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 136:1601-1608, 2009
30. Beasley RP, Hwang LY, Lin CC, et al: Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22,707 men in Taiwan. Lancet 2:1129-1133, 1981
31. Tsukuma H, Hiyama T, Tanaka S, et al: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797-1801, 1993 (Pubitemid 23174709)
32. Yu MW, Chen CJ: Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol 17:71-91, 1994
33. Chen JD, Yang HI, Iloeje UH, et al: Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 138:1747-1754, 2010
34. Centers for Disease Control and Prevention: International Classification of Diseases, Ninth Revision (ICD-9). http://www.cdc.gov/nchs/icd/icd9.htm
35. Wu CY, Kuo KN, Wu MS, et al: Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 137:1641-1648.e1-2, 2009
36. Lai MN, Wang SM, Chen PC, et al: Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 102:179-186, 2010
37. Cheng CL, Kao YH, Lin SJ, et al: Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 20:236-242, 2011
38. National Health Research Institutes: National Health Insurance Research Database. http://www.nhri.org.tw/nhird/date-01.html#-edn1
39. Centers for Disease Control, Department of Health, Taiwan: Guideline for communicable disease surveillance. http://www.cdc.gov.tw/public/data/ 92271549671.pdf
40. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 42:1208-1236, 2005 (Pubitemid 43112690)
41. WHO Collaborating Center for Drugs Statistics Methodology: ATC Index with DDDs 2003. Oslo, Norway, WHO, 2003
42. Chiang CJ, Chen YC, Chen CJ, et al: Cancer trends in Taiwan. Jpn J Clin Oncol 40:897-904, 2010
43. Yang HI, Lu SN, Liaw YF, et al: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347:168-174, 2002
44. Reddy BS, Wang CX, Kong AN, et al: Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 66:4542-4546, 2006
45. Hoffmeister M, Chang-Claude J, Brenner H: Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: A population-based case-control study. Int J Cancer 121:1325-1330, 2007 (Pubitemid 47293801)
46. Yang X, Ma RC, So WY, et al: Low triglyceride and nonuse of statins is associated with cancer in type 2 diabetes mellitus: The Hong Kong Diabetes Registry. Cancer 117:862-871, 2011
47. Ulmer H, Borena W, Rapp K, et al: Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer 101:1202-1206, 2009
48. Danesh FR, Sadeghi MM, Amro N, et al: 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci U S A 99:8301-8305, 2002 (Pubitemid 34651047)
49. Blanco-Colio LM, Villa A, Ortego M, et al: 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 161:17-26, 2002 (Pubitemid 34214817)
50. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21:1712-1719, 2001 (Pubitemid 34219772)
51. Shibata MA, Kavanaugh C, Shibata E, et al: Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 24:453-459, 2003 (Pubitemid 36432640)
52. Rao S, Porter DC, Chen X, et al: Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A 96:7797-7802, 1999 (Pubitemid 29328361)
53. Ye J, Wang C, Sumpter R Jr, et al: Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A 100:15865-15870, 2003 (Pubitemid 38021081)
54. Mallat A, Preaux AM, Blazejewski S, et al: Effect of simvastatin, an inhibitor of hydroxymethylglutaryl coenzyme A reductase, on the growth of human Ito cells. Hepatology 20:1589-1594, 1994 (Pubitemid 24359074)
55. Rombouts K, Kisanga E, Hellemans K, et al: Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol 38:564-572, 2003 (Pubitemid 36560640)
56. Targher G, Bertolini L, Padovani R, et al: Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 46:1126-1132, 2007 (Pubitemid 46669732)
57. Lee MH, Yang HI, Wang CH, et al: Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 41:2894-2900, 2010
58. Hui JM, Kench J, Farrell GC, et al: Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 17: 873-881, 2002
59. Gopal K, Johnson TC, Gopal S, et al: Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 44: 335-340, 2006 (Pubitemid 44214872)
60. Ikeda M, Abe K, Yamada M, et al: Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44:117-125, 2006 (Pubitemid 44049145)
61. Oberti F, Pilette C, Rifflet H, et al: Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. J Hepatol 26:1363-1371, 1997 (Pubitemid 27346651)
62. Trebicka J, Hennenberg M, Laleman W, et al: Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 46: 242-253, 2007 (Pubitemid 47171941)
63. Jasinska M, Owczarek J, Orszulak-Michalak D: Statins: A new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 59:483-499, 2007
64. Zafra C, Abraldes JG, Turnes J, et al: Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 126:749-755, 2004 (Pubitemid 38298323)
65. Kashani A, Phillips CO, Foody JM, et al: Risks associated with statin therapy: A systematic overview of randomized clinical trials. Circulation 114: 2788-2797, 2006 (Pubitemid 46018281)